Herpes zoster - 带状疱疹https://en.wikipedia.org/wiki/Shingles
带状疱疹 (Herpes zoster) 是一种病毒性疾病,表现为局部出现疼痛性皮疹并伴有水泡。皮疹通常呈单侧、宽条纹分布在身体或面部。皮疹出现前 2–4 天,患处可能出现刺痛或局部疼痛。部分患者仅有发热、头痛或乏力,而无典型皮疹。皮疹一般在 2–4 周内自行痊愈;但有些人会出现持续性神经疼痛,可持续数月甚至数年,这种情况称为带状疱疹后神经痛 (PHN)。免疫功能低下者可能出现广泛皮疹;若累及眼部,可能导致视力丧失。估计约有三分之一的人在一生中的某个阶段患过带状疱疹 (Herpes zoster)。该病多见于老年人,儿童亦可罹患。

水痘(Varicella)是由水痘-带状疱疹病毒初次感染引起,通常发生在儿童或青春期。水痘痊愈后,病毒可在神经细胞中潜伏多年,随后可能重新激活,导致带状疱疹 (Herpes zoster)。病毒沿神经纤维向皮肤末梢传播,形成水泡。带状疱疹爆发期间,接触到病毒的未曾感染水痘者可能因水泡而患上水痘。

病毒重新激活的危险因素包括年龄增长、免疫功能低下以及近期(如 18 个月内)感染水痘。水痘-带状疱疹病毒与单纯疱疹病毒同属疱疹病毒家族,但二者不同。

带状疱疹 (Herpes zoster) 疫苗可将发病风险降低 50%–90%,并显著降低带状疱疹后神经痛的发生率;即使发病,疫苗也能减轻病情的严重程度。若在皮疹出现后 72 小时内开始使用阿昔洛韦 (acyclovir) 等抗病毒药物,可缩短疾病持续时间并减轻症状。

治疗
若皮疹迅速扩散,请尽快就医接受抗病毒治疗。抗病毒药物和神经痛药物均为必要治疗。患者应充分休息并避免饮酒。
#Acyclovir
#Fancyclovir
#Valacyclovir

#Gabapentin
#Pregabalin
☆ 德国 Stiftung Warentest 2022 年的结果显示,消费者对 ModelDerm 的满意度仅略低于付费远程医疗咨询。
  • 脖子和肩膀上带状疱疹水泡
  • 带状疱疹 ― 第 5 天;如果开始治疗,疾病症状通常会在五天左右消失。
  • 如果带状疱疹广泛传播,如果抗病毒治疗延迟,患者可能会长时间出现疼痛的水泡。
  • 疤痕可能是带状疱疹导致的,即使体内的疱疹病毒已经消失,疤痕仍可能持续很长时间。
  • 如果额头受到影响,往往会伴随头痛。若病变波及鼻周围区域,请务必检查视力是否正常。
  • 此病例展示了带状疱疹的典型皮节分布。
  • 带状疱疹 ― Day1
  • 带状疱疹 ― Day2
  • 带状疱疹第 6 天 ― 尽管病变不再进展,但硬皮和疤痕可能会持续一个多月。
  • 在带状疱疹的晚期,痂皮和红斑可能持续1个月以上。
  • 带状疱疹即使治愈后,也可能留下疤痕。
  • 带状疱疹;伤疤
References Herpes Zoster and Postherpetic Neuralgia: Prevention and Management 29431387
带状疱疹是由导致水痘的水痘带状疱疹病毒重新激活引起的,在美国每年影响约 100 万人,终生患病风险为 30%。免疫系统较弱的人更容易患带状疱疹,症状通常以不适、头痛和轻度发热开始,然后在出现皮疹前几天出现异常的皮肤感觉。这种皮疹通常局限于身体的特定区域,约在一周至十天内从透明水泡演变为结痂的溃疡。皮疹出现后 72 小时内及时使用抗病毒药物治疗 (acyclovir, valacyclovir, or famciclovir) 至关重要。带状疱疹后神经痛是常见并发症,表现为受累部位的长期疼痛,约有五分之一的患者受影响。治疗通常需要持续使用加巴喷丁、普加巴林或某些抗抑郁药,并可配合利多卡因或辣椒素等外用药。建议 50 岁及以上的成年人接种水痘带状疱疹病毒疫苗,以降低发病风险。
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
 Epidemiology, treatment and prevention of herpes zoster: A comprehensive review 29516900
Herpes zoster 在 50 岁及以上的人群、免疫系统较弱的人群以及服用免疫抑制剂的人群中更常见。它是由水痘带状疱疹病毒重新激活引发的,水痘带状疱疹病毒与引起水痘的病毒相同。发烧、疼痛和瘙痒等症状通常先于特征性皮疹出现。最常见的并发症是带状疱疹后神经痛,即皮疹消失后持续的神经疼痛。与带状疱疹相关的危险因素和并发症因年龄、免疫健康状况和开始治疗的时间而异。60 岁及以上人士接种疫苗已被证明可显著减少带状疱疹和带状疱疹后神经痛的发生。在皮疹出现后 72 小时内开始使用抗病毒药物和止痛药,可以减轻带状疱疹和带状疱疹后神经痛的严重程度和并发症。
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
 Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines 36560671 
NIH
批准前的临床试验显示,带状疱疹活疫苗的有效率约为 50%–70%,而重组疫苗的有效率更高,为 90%–97%。真实世界研究也证实了这些结果,显示活疫苗的有效率约为 46%,重组疫苗的有效率约为 85%。
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.